ORYZON in San Francisco during the 35th Annual J.P. Morgan Healthcare Conference

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, will hold one on one meetings in San Francisco to discuss investment and pharmaceutical partnership opportunities during the 35th Annual J.P. Morgan Healthcare Conference. In addition, any investor attending the conference that wish to meet with Oryzon’s management can also contact our IR firm the Trout Group ([email protected]) and our IR Director Anna Baran-Djokovic at [email protected].

Click here to see the full Press Release